A randomized, double blind, placebo controlled study to evaluate the efficacy and safety of mirabegron 50 mg versus placebo in patients with neurogenic detrusor overactivity
Latest Information Update: 29 Jul 2024
At a glance
- Drugs Mirabegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms MIRAGE
- 22 Nov 2020 Results (n=66) of analysis assessing CV safety of mirabegron in patients with spinal cord injury or multiple sclerosis presented at the 50th Annual Meeting of the International Continence Society
- 15 Sep 2017 Status changed from recruiting to completed, as per results presented at the 47th Annual Meeting of the International Continence Society.
- 24 May 2016 New trial record